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Abstract
Background—Recent animal studies and clinical trials suggest that thiazolidinediones, a class of
oral antidiabetic agents, are efficacious in reducing inflammation, yet no studies have evaluated
their effectiveness in preventing flares. We examined the association between thiazolidinedione
use and ulcerative colitis (UC)-related flares.
Methods—We conducted a retrospective cohort study using administrative data from 87 health
plans across 33 states. Individuals with both UC and diabetes were identified using administrative
definitions. Exposure to thiazolidinediones or other oral antidiabetic agents was ascertained
through outpatient pharmacy claims. The primary outcome was occurrence of a UC flare defined
by: 1) a new prescription for oral steroids, infliximab, or oral/rectal salicylates, or 2) a claim for
colectomy. Secondary analyses analyzed outcomes separately. We estimated hazard ratios (HRs)
and 95% confidence intervals (CIs) using Cox proportional hazards regression after matching each
thiazolidinedione user to a comparable oral antidiabetic user on propensity score.
Results—This study included 142 thiazolidinedione and 468 other oral antidiabetic users with a
mean follow-up of 7.3 and 6.2 months, respectively. Thiazolidinedione use was not associated
with UC-related flares as measured by the composite outcome (HR = 1.05, 95% CI: 0.66, 1.68).
However, thiazolidinedione use was associated with a nonsignificant reduction in risk of oral
steroid use when analyzed as a separate outcome (HR = 0.53, 95% CI: 0.20, 1.44).
Conclusions—Thiazolidinediones do not provide any benefit over other oral antidiabetics in
preventing UC-related flares as measured by our primary composite outcome. However,
thiazolidinedione use may reduce the risk of more significant disease flares requiring oral steroid
treatment.
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ulcerative colitis; thiazolidinediones; epidemiology
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects nearly
500,000 Americans.1,2 The clinical course is typically relapsing and remitting: patients
experience flares of their illness with symptoms of abdominal pain, diarrhea, rectal bleeding,
and extra-intestinal manifestations, followed by periods of remission. Thus, the goals of
therapy are twofold: 1) to treat disease flares (induction of remission) and 2) to prolong the
length of time between flares (maintenance of remission). Despite the morbidity and
mortality associated with UC,3 limited treatment options exist and additional therapeutic
agents are needed. Thiazolidinediones, inhibitors of PPAR gamma,4 were introduced to the
US market in 1997. Although currently indicated for the treatment of type 2 diabetes
mellitus (“diabetes”),5 preclinical data and a recent randomized controlled trial have
demonstrated the efficacy of rosiglitazone (one member of the thiazolidinedione class) for
the induction of remission in UC patients with active disease.6–9 Yet the effectiveness of
thiazolidinediones in the maintenance of UC remission has not been comprehensively
evaluated.
Diabetes is one of the most common chronic illnesses in the US, with a prevalence of 8%.10
Based on the combined prevalence of UC and diabetes, a substantial percentage of
Americans may be affected by both conditions. UC may be particularly problematic in
patients with coexisting diabetes because oral steroids, a mainstay of UC treatment, can
exacerbate hyperglycemia. Therefore, preventing UC flares in these patients is of particular
importance.
Thiazolidinediones are considered second-line oral medications, reserved for diabetics who
fail to achieve metabolic goals on metformin therapy. However, if thiazolidinediones are
effective in maintaining UC remission in diabetic patients, there would be a strong argument
to move this class to first-line therapy in diabetic patients with UC. Additionally, since few
medications have been shown to maintain remission in UC, thiazolidinediones could have a
role in the primary treatment of UC patients with or without diabetes. Therefore, we
performed an exploratory retrospective cohort study using administrative data to examine




We conducted a retrospective cohort study using administrative claims data from the
PharMetrics Patient-Centric Database (IMS Health, Watertown, MA) during January 1,
2000 to December 31, 2005. This longitudinal, individual-level database included 87 health
plans across 33 states in the US. Data included inpatient and outpatient diagnoses and
procedures, as well as retail and mail-order prescription records. Demographic information
and start and stop dates for plan enrollment and pharmacy benefits were available. All
records used in the analysis were deidentified; therefore, this study was exempt from UNC
Institutional Review Board review.
Sample Population
Individuals in the study cohort were required to 1) be 18 to 64 years old, 2) meet the
administrative definitions for both diabetes and UC during the time period from January 1,
1995 to May 31, 2005, and 3) have at least 180 days of claims history prior to study entry.
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We defined diabetic individuals as having two or more claims of ICD-9 250.XX and at least
one oral antidiabetic medication dispensed.11 UC was defined by having three or more UC
claims (ICD-9 556.XX), or one IBD medication and one UC claim.2
Exposure and Outcome Definitions
Our primary analysis included a cohort of prevalent users of the following oral antidiabetic
medication classes: thiazolidinediones (rosiglitazone and pioglitazone), meglitinides,
nateglinides, sulfonylureas, biguanides, exenatides, and alpha-glucose inhibitors. Individuals
were classified as “thiazolidinedione users” if they were dispensed either rosiglitazone or
pioglitazone alone or in combination with another oral antidiabetic drug, otherwise, they
were classified as “other oral antidiabetic users.”
In a secondary analysis we restricted the study population to a subcohort of “new-users” of
oral antidiabetic agents (i.e., individuals without a prescription for an oral antidiabetic
medication dispensed in the 90 days prior to study entry).12
Due to the lack of clinical information in administrative databases, the primary study
outcome, the occurrence of a UC-related flare, was defined as any of the following events:
1) a new prescription dispensed for an oral steroid (days supplied ≥14), infliximab, or an
oral or rectal salicylate, or 2) a claim for colectomy. For oral steroids, we required a
minimum of 14 days supplied to increase the specificity of this definition for UC flares by
excluding steroid use for other acute indications such as respiratory, dermatologic, or other
inflammatory conditions. Individuals using oral or rectal salicylates during the 90 days prior
to study entry (presumably those on maintenance therapy) were not eligible for the specific
outcome of a new prescription for an oral/rectal salicylate. Subanalyses examined the
outcomes of a new prescription for oral steroids and oral/rectal salicylates separately.
Covariates
Data on potential confounders were obtained from the inpatient, outpatient, and pharmacy
claims and included age at study entry, sex, geographic region (East, Midwest, South, West),
insurance type (Medicaid versus commercial), concomitant medication use (insulin, 6-
mercaptopurine, imuran, methotrexate, entocort, oral and rectal salicylates, and
adalimumab), comorbidities (based on ICD-9 codes from the Deyo implementation of the
Charlson comorbidity score, used separately, not as a score), calendar year, and healthcare
utilization (total prescriptions in 180 days prior study entry [0–13, 14–27, >28] and number
of days-in-claims 180 days prior to study entry [0–5, 6–11, >12]).
Cohort Entry and Exit
Follow-up began on the day of the first oral antidiabetic prescription dispensed after the
individual had one claim for UC, one claim for diabetes, and 180 days of claims history.
Individuals who did not fulfill the administrative criteria for UC and diabetes were
subsequently excluded from analysis. Individuals who had a prescription for an oral steroid
or infliximab in the 90 days prior to study entry or a claim for colectomy in the 180 days
prior to study entry were excluded. Follow-up continued until the occurrence of 1) the
primary outcome, 2) a lapse in plan enrollment/pharmacy benefit of >30 days, 3) stopping of
baseline oral antidiabetic medication, 4) end of the study period (May 31, 2005), or 5)
reaching 65 years of age. Individuals who stopped taking their medication exited the cohort
30 days after the last dispensing (+ days supplied), which is usually 90 days after the last
dispensing. Additionally, members of the other oral antidiabetic group exited the cohort if
they started thiazolidinedione treatment (exit date was defined as the date that the
thiazolidinedione prescription was dispensed).
Lund et al. Page 3














Propensity Score Model Analysis—Descriptive statistics were reported for continuous
variables as means with standard deviations and for categorical variables as counts and
percentages. To control for measured confounders, we developed a propensity score model
using the administrative claims data to quantify the probability that a person was treated
with a thiazolidinedione.13 Covariates included in the propensity score were selected
according to a two-step process. We first constructed an outcome model identifying
independent predictors of UC-related flares (P < 0.1) using the variables shown in Table 1.
Subsequently, we consulted subject matter experts to identify additional predictors of UC-
related flares.14 We used multivariate logistic regression to estimate propensity scores for
each individual in the prevalent cohort and new-user subcohort separately. Using the
predicted propensity scores from our model, we attempted to match all thiazolidinedione
users with other oral antidiabetic users through 5-to-1 greedy matching.15 Matching on
propensity score is one technique commonly used to control for measured confounding in
observational studies.
Analysis—Analyses were performed for the prevalent cohort and the new-user subcohort
separately. We estimated the association between thiazolidinedione use and UC-related
flares using Cox proportional hazards regression before and after matching on propensity
score. Subanalyses of the new oral steroid and oral or rectal salicylate outcomes were
examined separately among prevalent users. All data analysis was performed in SAS 9.2
(SAS Institute, Cary, NC).
RESULTS
Descriptive Statistics
Using the administrative definitions described above, we identified 31,184 individuals with
UC from January 1, 1995 to May 31, 2005. Within this group we identified 610 individuals
from January 1, 2000 to May 31, 2005 with UC and diabetes, of which 142 were prevalent
thiazolidinedione users and 468 were other oral antidiabetic users. Thiazolidinedione and
other oral antidiabetic users had similar baseline characteristics, likely because oral
antidiabetic prescribing is not influenced by factors associated with the UC-related flares.
Comparing thiazolidinedione users to other oral antidiabetic users in the prevalent user
cohort before propensity score matching, the mean age was 54 (SD 7.0) versus 53 years (SD
7.6), the percentage of females was 43% versus 44%, and the regional distribution was East
(25% versus 22%), Midwest (30% versus 34%), South (32% versus 24%), and West (13%
versus 20%). There were slightly more thiazolidinedione users with previously insulin use
(19.7% versus 9.2%) and cardiovascular comorbidities (4.2% versus 1.5%). The median
duration of follow-up among prevalent thiazolidinedione users was 7.3 months, compared to
6.2 months for other oral antidiabetic users.
The new-user subcohort consisted of 260 individuals: 54 thiazolidinedione and 206 other
oral antidiabetic users. Similar to the prevalent user cohort, baseline characteristics in the
new-user subcohort did not substantially differ by medication group, with the exception of
prior insulin use (18.5% versus 4.4%) and comorbid diabetes with chronic complications
(11.1% versus 2.4%) (data not shown). The median duration of follow-up in the new-user
subcohort was 6.2 months among thiazolidinedione users and 6.4 months among other oral
antidiabetic users.
Propensity Score Model and Matching Results
As a result of the first step in the covariate selection process, prior insulin and
immunomodulator use and prior cardiovascular and peripheral vascular comorbidities were
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entered into the propensity score model. Next we added age at study entry, sex, region,
number of days-in-claims, number of prescriptions in the 180 days prior to study entry, and
calendar year at study entry to the final propensity score model based on expert opinion of
clinically relevant factors. In the prevalent-user cohort, propensity scores ranged from 0.09–
0.79 with a median of 0.24 for thiazolidinedione users and from 0.06–0.60 with a median of
0.21 for other oral antidiabetic users. Using the 5-to-1 matching algorithm,15 we matched
138 out of 142 (97%) thiazolidinedione users to comparable other oral antidiabetic users
(Supplementary Fig. 1, top panel).
In the new-user subcohort, propensity scores ranged from 0.06–0.83 with a median of 0.28
for thiazolidinedione users and from 0.01–0.75 with a median of 0.15 for other oral
antidiabetic users. Within this cohort, we matched 50 out of 54 (93%) thiazolidinedione
users to comparable other oral antidiabetic users. (Supplementary Fig. 1, bottom panel).
Table 1 shows the distribution of baseline characteristics among the prevalent users in both
exposure groups, after matching on propensity scores. As expected, the prevalences of the
factors included in the propensity score model were well balanced across exposure groups.
In addition, most other covariates were also balanced between the two exposure groups, with
the exception of prior entocort use (0% versus 3.6%) and prior diagnosis of mild to
moderate diabetes (87.7% versus 76.1%). Similar results were found in the matched new-
user subcohort (data not shown).
Regression Model Results
Table 2 reports the number of events, total person-years, and incidence rates of UC-related
flares per 100 person-years by exposure group. These results are presented for the
composite, new oral steroid, and new oral/rectal salicylate endpoints in the prevalent cohort
and the new-user subcohort for the unmatched analysis. Multiple endpoints were reached on
the same day. Among prevalent users, three had simultaneous oral steroid and oral salicylate
prescriptions, two had oral steroid and rectal salicylate prescriptions, and two had oral and
rectal salicylate prescriptions. Among new users, one had simultaneous oral steroid and
rectal salicylate prescriptions and another had oral and rectal salicylate prescriptions.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for each endpoint comparing
thiazolidinedione users to other oral antidiabetic users are reported in the two cohorts. In the
crude analysis, the hazard for UC-related flares among individuals dispensed
thiazolidinediones was similar to that among individuals dispensed other oral anti-diabetic
medications in prevalent users (HR = 0.90, 95% CI: 0.63, 1.30) and in new users (HR =
1.12, 95% CI: 0.64, 1.95). After matching on propensity score, the hazard ratio remained
relatively unchanged for prevalent users (HR = 1.05, 95% CI: 0.66, 1.68) (Fig. 1A) and new
users (HR = 1.41, 0.65, 3.05).
We conducted subanalyses for the new oral steroid endpoint and new oral/rectal salicylate
endpoint in the prevalent user cohort utilizing the original propensity score model, matching
algorithm, and Cox proportional hazards model (Table 2). We were unable to replicate the
subanalysis in the new-user subcohort due to small numbers. In the oral steroid outcome
analysis we found a protective, non-significant association between thiazolidinedione use
and a new oral steroid prescription when compared to other oral antidiabetic use before (HR
= 0.46, 95% CI: 0.20, 1.08) and after (HR = 0.53, 95% CI; 0.20, 1.44) matching (Fig. 1B). A
subanalysis of the outcomes of oral steroids and/or infliximab yielded essentially identical
results (data not shown). In the oral/rectal salicylate analysis, we found no association
between thiazolidinedione use and a new oral or rectal salicylate prescription before (HR =
1.06, 95% CI: 0.70, 1.60) or after (HR = 1.27, 95% CI: 0.73, 2.20) matching.
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We conducted a retrospective cohort study of individuals with UC and diabetes using a large
administrative claims database to examine the effectiveness of thiazolidinediones, as
compared to other oral antidiabetic medications, in preventing UC-related flares. In this
exploratory analysis we found that the hazards for UC flares, indicated by a composite
outcome including 1) a new prescription for oral steroids, infliximab, or oral/rectal
salicylates, or 2) a claim for colectomy, were not different for individuals dispensed
thiazolidinediones and other oral antidiabetic medications. However, a subanalysis of the
outcome of oral steroids among prevalent users demonstrated a non-significant protective
effect of thiazolidinediones. Although this study was underpowered to detect an effect in
this subanalysis, the magnitude of this effect (adjusted HR = 0.53) is quite substantial.
Furthermore, the endpoint of oral steroid use is clinically meaningful (indicator of moderate
to severe flares). We believe the findings of this exploratory study justify further
examination of the possible protective effects of thiazolidinediones in larger cohort studies
and/or clinical trials. However, thoughtful consideration of the overall risk/benefit trade-off
is warranted in light of recent studies detailing an increased risk of cardiovascular and
fracture risks among thiazolidinedione users.16–18
To implement our study we created a prevalent user cohort and new-user subcohort. The
prevalent user cohort included individuals who may have been using oral antidiabetic drugs
for a period of time prior to study entry. Including these individuals in our analysis increased
the sample size and statistical efficiency, but may have introduced bias if the risk of the
outcome varied with time on treatment.12,19 In addition, measured covariates prior to study
entry may be affected by oral antidiabetic medication use, resulting in bias.12,20 To avoid
these potential biases, we also conducted an analysis within a cohort of new users,
individuals who did not use oral antidiabetic medications in the 90 days prior to study entry.
This analysis confirmed the results of the prevalent user analysis. We also sought to
minimize confounding by indication and “healthy user” bias by comparing thiazolidinedione
users to other oral antidiabetic users rather than individuals not using diabetic medications.21
Lastly, we used propensity score matching based on a 5-to-1 greedy algorithm to maximize
the number and quality of thiazolidinedione to other oral antidiabetic user matches.15 In both
the prevalent user cohort and new-user subcohort, matches were made for over 90% of all
thiazolidinedione users. The resulting HRs from the Cox regression models represent the
effect of thiazolidinediones in thiazolidinedione users (or the “treatment effect in the
treated”).22
Our study has several limitations that should be considered when interpreting the results.
Our study population of individuals with UC and diabetes was defined using administrative,
not clinical data, and is therefore subject to misclassification error. However, to minimize
this bias we applied stringent algorithms for both conditions modeled after previously
published criteria.1,2,12 The use of stringent inclusion criteria requiring multiple healthcare
contacts and/or prescription medication use may limit the generalizability of these findings
to patients with milder disease requiring less frequent medical care. However, exclusion of
such individuals with milder disease should be nondifferential with respect to exposure
status, and not introduce significant selection bias.
Our primary outcome measure was a composite marker for a UC-related flare. We made our
best effort to identify pharmacy and procedure claims that reflected true clinical UC flares,
but this measure is also subject to misclassification. Our definition was consistent with one
utilized by Lewis et al in the General Practice Research Database, which defined an
exacerbation of IBD to be a new prescription for either an oral aminosalicylate or an oral
steroid. Restricting to new oral steroid prescriptions, the authors found an 85% positive
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predictive value for the administrative definition of a flare and clinical confirmation from a
physician.23,24 Confounding by indication, based on severity of diabetes, is another possible
limitation of this analysis. We compared users of thiazolidinediones with users of other oral
antidiabetic medications, and every effort was taken to further minimize this possibility by
analyzing several indicators of diabetes severity (prior insulin use, diabetes complications,
and comorbid conditions based on the Deyo implementation of the Charlson Comorbidity
Index). In addition, we could not control for unmeasured variables not contained within
administrative data including lifestyle factors (diet, smoking, exercise) and family history of
IBD. However, we have no reason to suspect that these factors would be associated with
thiazolidinedione exposure and thus represent significant unmeasured confounding.
In this analysis we only studied the effectiveness of thiazolidinediones in UC patients with
diabetes in a commercially insured population. Therefore, these results may not be
generalizable to UC patients without comorbid diabetes or to noncommercially insured
populations. Further, due to the relatively small number of thiazolidinedione users in the
study and frequent switching between rosiglitazone and pioglitazone use, we were unable to
compare the effectiveness of these two medications separately.
Despite these limitations, our study has a number of strengths. We were able to identify a
diverse cohort of individuals with UC and diabetes encompassing a range of ages, regions,
and comorbid conditions. Although our study did not randomly assign thiazolidinedione
treatment, we were able to observe the potential effectiveness of the drug for preventing UC
flares under “real-world” conditions. The use of propensity score matching allowed us to
efficiently control for measured confounding, despite the relatively small number of
outcomes in this study population.
All medication exposure information was determined based on outpatient pharmacy
dispensing records, thus minimizing reliance on patient recall and/or physician
documentation. Despite this advantage, we did not have information on patient compliance
of the dispensed drug and were unable to capture medication use obtained through physician
samples.
Finally, follow-up for our study was relatively long, averaging greater than 6 months in both
exposure groups. A randomized controlled trial of this size would have been logistically and
financially challenging to implement.
In conclusion, the results of this exploratory study suggest that thiazolidinedione use does
not decrease the risk of total UC-related flares (defined by a composite outcome of new
prescriptions for oral steroids, infliximab, oral/rectal salicylates, or colectomy), as compared
to other oral antidiabetic use within a population of individuals with UC and diabetes.
However, we observed a nonsignificant tendency toward decreased oral steroid prescriptions
in thiazolidinedione users, a marker for moderate to severe UC flares. Because few
treatments for UC are currently available, pharmacoepidemiology studies such as this which
evaluate the effectiveness of nongastrointestinal medications on the course of UC are
especially valuable. These findings support the need for larger cohort studies and/or a
prospective clinical trial to investigate the efficacy of thiazolidinediones in the maintenance
of remission for patients with UC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kaplan–Meier survival curves of individuals diagnosed with diabetes and UC comparing
relapse-free survival for those treated with thiazolidinediones (hatched lines) compared to
other oral antidiabetic medications. Hazard ratios were estimated using Cox proportional
hazards regression after matching on propensity score. (A) Relapse is defined by the
composite outcome of a new prescription for an oral or rectal aminosalicylates, oral steroids,
or infliximab, or colectomy (HR = 1.05, 95% CI: 0.66, 1.68). (B) Relapse is defined as a
new prescription for oral steroids only (HR = 0.53, 95% CI: 0.20, 1.44).
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TABLE 1
Characteristics of Prevalent Thiazolidinedione and Other Oral Anti-Diabetic Users with Ulcerative Colitis
After Matching on Propensity Score
TZD users Other OAD users
N=138 % N=138 %
Demographic information
 Age in years (mean (SE*)) 53.8 (7.0) 54.0 (7.2)
 Female gender 60 43.5 69 50
 Region – East 33 23.9 33 23.9
 Region – Midwest 42 30.4 38 27.5
 Region – South 45 32.6 47 34.1
 Region – West 18 13.1 20 14.5
 Medicaid 1 0.7 2 1.5
Prior medication use (90 days before study entry)
 Prior insulin use 24 17.4 22 15.9
 Prior immunomodulator use 6 4.4 3 2.2
 Prior methotrexate use 0 0 1 0.7
 Prior entocort use 0 0 5 3.6*
 Prior salicylate use 87 63 84 60.9
 Prior adalimumab use 0 0 0 0
Prior comorbid conditions (180 days before study entry)
 Peripheral vascular disease 6 4.4 5 3.6
 Cardiovascular disease 5 3.6 5 3.6
 Myocardial infarction 3 2.2 4 2.9
 Congestive heart failure 5 3.6 3 2.2
 Dementia 0 0 0 0
 Chronic obstructive pulmonary disease 12 8.7 6 4.4
 Rheumatologic disease 0 0 1 0.7
 Peptic ulcer disease 1 0.7 2 1.5
 Diabetes (mild to moderate)a 121 87.7 105 76.1
 Diabetes with chronic complicationsa 13 9.4 13 9.4
 Retinopathy, nephropathy, or neuropathy 8 5.8 8 5.8
 Hemiplegia or paraplegia 0 0 0 0
 Mild liver disease 0 0 2 1.5
 Moderate or severe liver disease 28 20.3 22 15.9
 Renal disease 4 2.9 4 2.9
 Any malignancy, including lymphoma and leukemia 5 3.6 6 4.4
 Metastatic solid tumor 0 0 1 0.7
 AIDS 0 0 0 0
Calendar time
 Year 2000 2 1.5 1 0.7
 Year 2001 4 2.9 5 3.6
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TZD users Other OAD users
N=138 % N=138 %
 Year 2002 18 13 18 13
 Year 2003 50 36.2 59 42.8
 Year 2004 56 40.6 46 33.3
 Year 2005 8 5.8 9 6.5
Healthcare utilization
 Days-in-claims (0–5) 36 26.1 38 27.5
 Days-in-claims (6–11) 59 42.8 61 44.2
 Days-in-claims (>12) 43 31.2 39 28.3
 Total prescriptions (0–13) 44 31.9 40 29
 Total prescriptions (14–27) 44 31.9 48 34.8
 Total prescriptions (>28) 50 36.2 50 36.2




Categories are not mutually exclusive based on differences in cohort definitions and the Deyo implementation of the Charlson comorbidity index.
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